RichardJamesTraversMDPhD
Hematology • Boston, MAHematologic Oncology, Hemophilia & Bleeding Disorder
Hematology Oncology Fellow
Dr. Travers is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
800 Washington St
Boston, MA 02111Phone+1 617-636-7227
Education & Training
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 2018 - 2021
University of Illinois College of MedicineClass of 2018
Certifications & Licensure
MA State Medical License 2018 - 2025- American Board of Internal Medicine Internal Medicine
Publications & Presentations
PubMed
- Endothelium as a Source of Cardiovascular Toxicity From Antitumor Kinase Inhibitors.Richard J Travers, Alec Stepanian, Iris Z Jaffe
Arteriosclerosis, Thrombosis, and Vascular Biology. 2024-10-01 - Identifying mitigating strategies for endothelial cell dysfunction and hypertension in response to VEGF receptor inhibitors.Nicholas D Camarda, Qing Lu, Dawn M Meola, Joshua J Man, Zeyuan Song
Clinical Science. 2024-09-18 - 2 citationsROCK and Rolling Towards Predicting BCR-ABL Kinase Inhibitor-Induced Vascular Toxicity.Jenica N Upshaw, Richard Travers, Iris Z Jaffe
JACC. Cardiooncology. 2022-09-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
